A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe
NCT05123950 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 304
Last updated 2021-11-17
Summary
The purpose of this observational study is to collect real-world data that describes treatment patterns and clinical outcomes in participants with first line recurrent/metastatic squamous cell carcinoma of the head \& neck (1L R/M SCCHN).
Conditions
- Squamous Cell Carcinoma of the Head and Neck
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-01
- Primary Completion
- 2021-03-19
- Completion
- 2021-03-19
Countries
- United States
Study Locations
More Related Trials
-
Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis
NCT06905145 ·Status: RECRUITING
-
Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.
NCT06869473 ·Status: RECRUITING ·Phase: PHASE2
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
NCT02128906 ·Status: RECRUITING ·Phase: PHASE2
-
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT00402545 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarker-based Study in R/M SCCHN
NCT03088059 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT00971932 ·Status: COMPLETED ·Phase: PHASE2
-
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
NCT02281955 ·Status: COMPLETED ·Phase: PHASE2
-
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
NCT03667482 ·Status: COMPLETED ·Phase: PHASE1
-
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT02277184 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Nivolumab in Patients With Head and Neck Cancer.
NCT04050761 ·Status: COMPLETED
-
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
NCT01911598 ·Status: COMPLETED ·Phase: PHASE1
-
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00513435 ·Status: COMPLETED ·Phase: PHASE2
-
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
NCT05057247 ·Status: COMPLETED ·Phase: PHASE2
-
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma
NCT05328024 ·Status: RECRUITING
-
SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
NCT02543476 ·Status: COMPLETED
-
Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT00805012 ·Status: TERMINATED ·Phase: PHASE2
-
Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.
NCT04672772 ·Status: COMPLETED
-
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
NCT03422536 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
NCT00882583 ·Status: TERMINATED ·Phase: PHASE1
-
Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT00705016 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck
NCT00139243 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
NCT01530997 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
NCT02609503 ·Status: COMPLETED ·Phase: PHASE2
-
Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
NCT00098631 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck
NCT01177956 ·Status: COMPLETED ·Phase: PHASE3